|Bid||252.60 x 0|
|Ask||253.00 x 0|
|Day's range||249.60 - 254.00|
|52-week range||194.47 - 273.80|
|Beta (5Y monthly)||0.22|
|PE ratio (TTM)||28.59|
|Earnings date||06 Feb 2024 - 12 Feb 2024|
|Forward dividend & yield||N/A (N/A)|
|1y target est||298.36|
Sobi® will present new data at the 65th Annual Meeting of the American Society of Hematology (ASH) in San Diego from the 9th to the 12th of December 2023. During the meeting several analyses will be presented in patients with haemophilia A, paroxysmal nocturnal hemoglobinuria (PNH), immune thrombocytopenia (ITP), relapsed or refractory diffuse large b-cell lymphoma, myelofibrosis, and haemophagocytic lymphohistiocytosis.
The Board of Directors of Swedish Orphan Biovitrum AB (publ) (Sobi®) (STO: SOBI) ("Sobi") has, as previously communicated, on 31 October 2023 resolved to issue redeemable and convertible series C shares and to, conditional upon subscription and payment from Svenska Handelsbanken AB, repurchase all issued series C shares, to secure Sobi's obligations under the outstanding incentive programmes. Svenska Handelsbanken AB has today subscribed for all 602,482 issued series C shares, and the new share
Swedish Orphan Biovitrum (BIOVF) delivered earnings and revenue surprises of -44.44% and 7.69%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?